Royalty Report: Drugs, Drug Discovery, Disease – Collection: 372425


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Drug Discovery
  • Disease
  • Diabetes Treatment
  • Therapeutic
  • obesity

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 372425

License Grant
Licensor, a nonprofit diabetes research center, diabetes clinic, and provider of diabetes education, grants to Licensee an exclusive, worldwide license under the Licensed Patents to make, have made, use, have used, sell, offer to sell, import, research, develop, commercialize and otherwise exploit Licensed Products in the Field.
License Property
The patents are titled
— Methods and Compositions for Modulating Adipocye Function;
— Bone Morphogenetic Proteins for Appetite Control; and,
— Bone Morphogenetic Proteins for The Treatment of Insulin Resistance.

Bone Morphogenetic Protein-7 (“BMP-7”) is a member of a family of proteins discovered in osteoinductive extracts of bone matrix and is a member of the transforming growth factor beta (“TGF-ß”) superfamily of proteins. We believe that the use of BMP-7 as a therapeutic product could potentially have a disease modification impact in osteoarthritis (“OA” and reduce and reverse organ fibrosis-related diseases such as CKD and Alport syndrome. Because studies have indicated that BMP-7 is capable of promoting the development of brown fat, which, in turn, may positively impact glucose metabolism and insulin sensitivity, we believe that BMP-7 could also be used to treat metabolic diseases.

Field of Use
The agreement aimed at utilizing “brown fat,” a type of fat that helps increase energy expenditure within the body, as a novel technique for managing obesity and diabetes.

The license to the intellectual property covering BMP7 technology includes a number of patented discoveries related to the use of the protein BMP7 to manipulate brown fat for the purpose of controlling glucose levels and managing weight. Based on these discoveries, Licensee plans to advance the BMP7 program into human clinical trials and ultimately hopes to develop an approved drug product that would aid in controlling these metabolic disease conditions that have reached epidemic proportions.

Patents Rights relates to, among other things, the use of BMP for weight control and as a treatment for insulin resistance

IPSCIO Record ID: 214173

License Grant
Pursuant to this agreement, the Australian Licensor, a non-profit organization, the owner of a Sand Rat colony based at an Australian University, and has agreed to make the Sand Rats available to the University for the purposes of the Project.

The Australian Licensee desires to collaborate with the Australian University for the Project using the Research Expertise and a license of all Intellectual Property in the result of the Project.

License Property
The license is for use of the Sand Rat colony for the project.
The Israeli Sand Rat is the only animal model which develops a broad spectrum of defects in food intake, body fat and diabetes comparable to similar defects measured in humans. For example, it is possible in the Israeli Sand rat to find 2 offspring from the same parents, one will remain lean and free from diabetes, while the other overeats and subsequently develops obesity. Both of these animals have exactly the same environmental influences – Why does one overeat.

By utilising the latest techniques available in molecular biology (gene fingerprinting) we will be able to determine the different genes being expressed in obese animals – isolate these genes and determine their role in obesity development. Novel genes uncovered will be patented and their metabolic potential determined.

Field of Use
The primary aim of this research program is to discover novel genes that will be integral to the development of new therapeutic approaches directed at the treatment and prevention of obesity.

The Project means scientific research using the Research Expertise into the role of potential pharmaceutical agents on food intake, body weight control and parameters of insulin resistance and diabetes as examined in studies into therapeutic regulators of food intake and appetite.

IPSCIO Record ID: 378328

License Grant
Licensee was granted an exclusive license to use the MP Patents and know-how to develop products for the development, commercialization and exclusive license of MLR-1023 On October 20, 2021, Licensee expanded the an exclusive licensing agreement with Licensor to include two additional clinical indications for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation.
License Property
MLR-1023 (tolimidone) is being developed as a novel therapeutic for Type 1 diabetes with a focus on C-peptide positive patients. MLR-1023, a lyn kinase activator, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b Type 2 diabetes studies.
Field of Use
The  license of MLR-1023 (tolimidone) is for the purpose of developing a novel therapeutic for Type 1 diabetes.

Field of use is for the treatment of diabetes as well as for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation diseases and conditions.

Diabetes is a chronic (long-lasting) health condition that affects how your body turns food into energy. Most of the food you eat is broken down into sugar (also called glucose) and released into your bloodstream. When your blood sugar goes up, it signals your pancreas to release insulin.

Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver.

Pulmonary inflammation is acute lung inflammation.  In the lung, inflammation is usually caused by pathogens or by exposure to toxins, pollutants, irritants, and allergens. During inflammation, numerous types of inflammatory cells are activated.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.